ClinicalTrials.gg
RecruitingNCT05943262Updated Aug 21, 2024

Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling

An observational study in Brain Tumor and Brain Cancer, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Brain Neoplasms by National Taiwan University Hospital — 4 open to participants now, 4 under way, none of them phase 3. Brain Neoplasms · National Taiwan University Hospital.

Started
2023
with 2 others
Observational
4 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Brain Neoplasms by National Taiwan University Hospital, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 13th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 15 studies in Brain Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

The research aims to develop a novel pathological technology, including rapid whole-mount tissue H\&E \& IHC staining protocol and high-resolution nonlinear optical microscopy imaging system, to intraoperatively assess brain tumor grade, types and other biological parameters.

Read the detailed description

Brain tumors, especially like glioma, the infiltrative growth pattern resulted in an indistinct margin against normal brain tissues. Surgery is currently the most effective method in prolonging patient's survival, the extent of tumor resection is therefore crucial to the overall outcome. Distinguishing the tumor type and grading can help neurosurgeons plan the intraoperative surgical strategies to cure the suffered patients. Feasible solutions to improve the extent of resections including fluorescence-guided surgery and intraoperative MR imaging are relatively indirect to judge the completeness of tumor resection and its margin; considering means like Moh's surgery performed in the dermatological practice, though it is reasonable to look at the resection proportion by pathological interpretation, it is very time consuming. Besides, many kinds of brain tumors can't be classified only by the outcomes of frozen pathology. There are several related studies trying to solve the problem, but the judgment criteria is not sufficient to meet the standard of modern pathological diagnosis. The research aims to acquire images by optical microscopy from both H\&E and IHC stained tissues, and to compare those images with slides obtained by standard pathological workflow in order to achieve accurate and rapid assessment of tumor categories and grading.

03

Conditions studied

  • Brain Tumor
  • Brain Cancer

Browse trials for

Keywords

  • brain tumor
  • brain cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients older than the age of 20 with diagnosis of brain tumor (both newly-diagnosed or recurrent) who are suitable and willing to receive resection surgery will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients older than the age of 20 with diagnosis of brain tumor (both newly-diagnosed or recurrent) who are suitable and willing to receive resection surgery.

Exclusion criteria

Exclusion Criteria:

  1. Patients who cannot give consent to participate in the study.
  2. The tumor samples failed to give a conclusive pathological diagnosis by standard pathological workflow.
  3. Patients who only receives surgery rather than resection surgery.
  4. Significant post-irradiation effect or radiation necrosis reported in the pathological examination.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • mesoscale nonlinear optical microscope + whole-mount H&E & IHC staining protocol

    Device: mesoscale nonlinear optical microscope

Interventions

  • Devicemesoscale nonlinear optical microscope

    The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.

06

What researchers measure

Primary outcomes

  1. Develop a standard whole-mount tissue processing protocol

    In this research, the investigators will try to create a standard staining protocol to perform rapid whole-mount H\&E and IHC staining on surgical brain tumor specimens, so that the cell morphology (ex: cell shape, cell size, etc) and cell types (ex: astrocytes, oligodendrocytes, T-cells, B-cells, etc) in the images of those tissues can be observed via nonlinear optical microscopy, and the treatment strategy can be set based on subtyping and grading the brain tumors by the pathologists.

    Time frame: 3 years

  2. Obtain images from H&E and IHC stained brain tumor tissues by nonlinear optical microscopy

    Images of brain tumor specimens will be taken by nonlinear optical microscopy and a image database of brain tumors can be created (ex: cell shape, cell size and cell density of different cells in human brain tissues).

    Time frame: 3 years

Secondary outcomes

  1. Distinguish between normal tissue and brain tumor and determine the extent and grade of the brain tumors

    By interpreting the images acquired from nonlinear optical microscope of the two staining methods and the images obtained by bright field microscope for pathologists with standard procedures, an attempt is made to distinguish between normal tissue and brain tumor and determine the extent and grade of those brain tumors (depending on tumor characteristics, such as hypercellularity, microvascular proliferation, necrosis, etc).

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2023
First posted
Jul 13, 2023
StartActual
May 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05943262
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
May 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 21, 2024

Study contacts

Kuo-Chuan Wang
Contact
wang081466@yahoo.com.tw
+886-23123456 ext. 263155
Yao-Chen Tseng
Contact
opiuy1234567@yahoo.com.tw
+886-33661552

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion